Introduction
============

The treatment strategy of trisomy 18 is controversial as the prognosis is lethal. Approximately 50% of newborns survive \>1 week while \>90% do not survive beyond 1 years of age. The medical progression of neonatal intensive care management in Japan has been previously established and the first described trisomy 18 infants were reported in 1960 ([@b1-mmr-13-03-2457],[@b2-mmr-13-03-2457]). The definition of the trisomy 18 syndrome, also known as common autosomal aneuploidy chromosomal abnormality due to the presence of an extra chromosome 18, using the standard G-banded karyotype allows for confirmation of the clinical diagnosis of multiple anomalies ([@b3-mmr-13-03-2457]). It is clinically associated with various major and minor multisystem anomalies, including cardiovascular, brain with neurological, renal, gastrointestinal, respiratory, and skeletal malformations ([@b4-mmr-13-03-2457],[@b5-mmr-13-03-2457]). Trisomy 18 is clinically associated with ≥50% of anomalies including craniofacial abnormalities such as prominent occiput, narrow bifrontal diameter, low-set and malformed auricles and micrognathia; hand and feet anomalies including clenched hand, overlapping of index finger and hypoplasia of nails; thorax deformities; inguinal hernia; small pelvis; male with cryptorchidism; cardiac and circulatory system, in particular ventricular septal defect (VSD), patent ductus arteriosus (PDA) and auricular septal defect. In addition, 10--50% of cases showed other craniofacial, hand, feet and thorax anomalies, cardiac with pulmonic stenosis, coarctation of aorta, renal anomaly with horseshoe defect, double ureter, hydronephrosis and polycystic kidney, while ≥50% of cases exhibited central nervous system anomaly with cerebellar hypoplasia, agenesis of corpus callosum, hydrocephalus, meningomyelocele and Dandy-walker malformation ([@b6-mmr-13-03-2457],[@b7-mmr-13-03-2457]). All the cases had severe mental and psychomotor disorders.

Epidemiologically, previously conducted studies have focused on trisomy 18 ([@b4-mmr-13-03-2457],[@b8-mmr-13-03-2457]--[@b23-mmr-13-03-2457]). Root and Carey ([@b9-mmr-13-03-2457]) reported that the incidence of trisomy 18 syndrome is as low as 1 in 8,000 births; however, this is the second highest incidence of chromosomal aberrations in live-born infants following trisomy 21. Findings of prevalence studies by Goldstein and Nielsen ([@b10-mmr-13-03-2457]) Forrester and Merz ([@b11-mmr-13-03-2457]) focusing on populations in Hawaii and Denmark, respectively, showed that live-born infants of trisomy 18 had an incidence of 1 in 8,000 to 1 in 10,000. By contrast, Bergin *et al* ([@b12-mmr-13-03-2457]) reported the incidence of trisomy 18 to be 1 of 555 conceptuses, with the most recently recorded frequencies in live-born infants in Dublin and Leicester in England being in the range of approximately 1 in 3,000. On the basis of the reported literature, the live birth prevalence of trisomy 18 ranges from 1/3,000 to 1/10,000 and the estimated average is approximately 1 in 6,000 ([@b3-mmr-13-03-2457],[@b9-mmr-13-03-2457]--[@b12-mmr-13-03-2457]). Gender differences during gestation have been previously identified, with a 4-fold higher incidence in female subjects compared to male subjects ([@b5-mmr-13-03-2457]). By contrast, Kuroki and Kurosawa ([@b24-mmr-13-03-2457]) reported no gender differences in trisomy 18, as indicated by data obtained from the prefecture birth defects monitoring program in Japan. An increase in the age of the parturient female leads to an increased risk of trisomy 21, as well as the development of trisomy. The recurrence risk of trisomy 18 has been analyzed and estimated at \<1% ([@b25-mmr-13-03-2457],[@b26-mmr-13-03-2457]). The precise mechanism of this syndrome is known to develop from an error in maternal meiosis, with the chromosomal abbreviation being due to maternal origin in \~96% of cases of trisomy 18 ([@b27-mmr-13-03-2457]).

When issues such as the medical treatment of newborns, genetic counseling and medical ethics arise, management with treatment strategy for this genetic trisomy syndrome is clinically essential ([@b6-mmr-13-03-2457]). The life prognosis of trisomy 18 is controversial as the outcome is usually lethal. Patients with long-term survival of trisomy 18 exhibited severe pschyomotor developmental delay. Thus, any approach to the treatment strategy and policy of a third-trimester fetus and live-born neonate with trisomy 18 is complicated, resulting in controversial findings. The primary issue involves the complexity surrounding the decision-making process regarding the treatment strategy immediately following birth in newborns diagnosed with trisomy 18. Rasmussen *et al* ([@b13-mmr-13-03-2457]), Crider *et al* ([@b18-mmr-13-03-2457]) and Irving *et al* ([@b19-mmr-13-03-2457]) reported that the important issues involved in the parental primary care of live-born infants with trisomy 18 is associated with a high neonatal and infantile mortality death rate. When a fetus is known to have trisomy 18, delivery by cesarean section is avoided due to ethics issues, as indicated by Norup ([@b28-mmr-13-03-2457]) in a study conducted in Denmark. The findings of that study showed consensus for physicians working in the perinatal and neonatal medical unit until 21 weeks with regard to trisomy 18 ([@b28-mmr-13-03-2457]). Irving *et al* ([@b19-mmr-13-03-2457]) reported that the prenatal diagnosis of trisomy 18 leads to a decision in support of pregnancy termination in 86% of cases ([@b19-mmr-13-03-2457]). Sociologically, the medical treatment for the neonatal to infantile periods with disabilities was found to be different for various countries depending on factors such as culture, religion, human rights, law and views on bioethics. Traditionally, a non-intervention approach in the newborn management of trisomy 18 and 13 has been previously utilized. Bos *et al* ([@b29-mmr-13-03-2457]) summarized these ethical issues, indicating that early diagnosis was extremely important for the avoidance of unnecessary surgical treatment. At present, trisomy 18 and 13 are considered to have a high mortality and survivors suffer from severe mental impairment and fail to thrive. Consequently, surgical procedures are withheld in the early stages of infancy to determine the outcome following the first few months ([@b6-mmr-13-03-2457]).

In Japan, the therapeutic policies for poor long-term life prognosis for trisomy 18 and 13 involve two controversial concepts: i) the provision of thorough affection and care and avoidance of excessive intensive treatment; or ii) the provision of active intensive treatment including resuscitation and surgery according to the clinical conditions of an infant in accordance with the wishes of the affected infant\'s parents ([@b14-mmr-13-03-2457],[@b30-mmr-13-03-2457]). However, there was insufficient evidence regarding the improvement of prognosis of trisomy 18 patients treated at the Neonatal Intensive Care Unit (NICU) who underwent surgery. Kosho *et al* ([@b14-mmr-13-03-2457],[@b31-mmr-13-03-2457]) studied 24 cases of trisomy 18 treated at the NICU, resulting in improved life prognosis as compared to previously reported data.

After written informed consent was obtained from the family members following genetic counseling, intensive treatment including resuscitation, intra-tracheal intubation, support of artificial ventilation, and surgical procedures was performed for long-term survival of trisomy 18 at the NICU of Dokkyo Medical University School of Medicine. In addition, active support management in the form of home nursing care in cooperation with the family was provided. In this study, in order to certify the clinical details and survival periods of trisomy 18 patients managed at the NICU level, we investigated a retrospective single-center study of 44 patients with trisomy 18, admitted to the Dokkyo Medical University School of Medicine over a period of \>20 years.

In addition, prior to performing this study, important factors regarding development of neonatal medicine over a period of \>20 years was considered. Thus, whether medical progress influenced improvement of the life prognosis of trisomy 18 patients over such a long study period was examined. The patients were divided into two groups and criteria considered included the general condition and life prognosis immediately following the delivery. The results provide useful information concerning genetic counseling for parents/guardians and life prognosis.

Patients and methods
====================

General
-------

The study comprised 6,183 newborn infants who were admitted to the NICU of Dokkyo Medical University Hospital in Japan, during the period of 1992--2012. The 21-year period was divided into two groups: group A constituted the first 11 years (1992--2002) and group B the second 10 years (2003--2012). Group A and B comprised 2,928 and 3,255 newborn patients, respectively. The newborn infants manifested minor and/or major external malformations or organ malformations that were observed during the clinical examinations by a neonatologist and pediatrician. The infants underwent a congenital chromosomal test and peripheral blood cells obtained were analyzed via the standard method of G-banding karyotype. A breakdown of the patient numerical autosomal trisomies identified 96 patients (1.55%), with trisomy 21; 44 patients (0.71%) with trisomy 18 including full trisomy, mosaic type and patients with an extra chromosome 18; and 17 patients (0.27%) with trisomy 13 were admitted to the NICU. Other chromosomal abnormalities exhibited included 2 patients with trisomy 8 mosaicism, 3 patients with 5p-syndrome and 4p-syndrome.

In this study, a retrospective single-center study was conducted using NICU medical records from 44 patients with trisomy 18 obtained at the Dokkyo Medical University Hospital. Group A comprised 20 patients and group B comprised 22 patients with trisomy 18. There were no cases of prenatal diagnostic screening for trisomy 18 prior to birth, thus all 44 cases were diagnosed after birth.

Statistical analysis
--------------------

Statistical analysis was performd to determine any significant differences between groups A and B. The positive effect of the NICU management and treatment was determined when no significant differences were observed for the two groups at delivery but there was a significant difference in the survival prognosis. The following statistical procedure was performed as establishment for it.

Continuous data during pregnancy and delivery were described as mean ± standard deviation, if normally distributed, or median (interquartile range), if not normally distributed. Comparisons between groups A and B for continuous variables were made using the unpaired t-test, if normally distributed, or Mann-Whitney U test, if not normally distributed. Categorical data were described as number and percentage, and differences were analyzed using Fisher\'s exact test.

The percentage survival was analyzed using Kaplan-Meier curves after establishing the longest survival time at 1 year. The survival curves were estimated according to the Kaplan-Meier method. The generalized Wilcoxon and log-rank tests were used to determine statistically significant differences for the prognosis of survival time at 180 days, 1 year and the entire investigated period of patients for groups A and B. The time periods were analyzed using SPSS version 22.0 for Windows (IBM Japan, Tokyo, Japan). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Clinical details at pregnancy and delivery
------------------------------------------

The statistical analysis results for groups A and B are shown in [Table I](#tI-mmr-13-03-2457){ref-type="table"}. None of the 44 patients with trisomy 18 syndrome had a family history of chromosomal abnormalities. The karyotypes of chromosomal abnormalities associated with chromosome 18 were identified in the 44 patients using a G-banding method. The result of karyotypes included the full type of trisomy 18 in 42 patients (95%), the mosaic type of trisomy 18 in 1 patient (2%), and the rare isodicentric chromosome 18, i.e., 46,XX,idic([@b18-mmr-13-03-2457])(p11.31) in 1 patient.

Of the 44 patients, 16 were males and 28 females. None of the patients underwent a prenatal diagnosis using the amniotic fluid marker test for trisomy 18. The term of delivery was 29--42 gestational weeks, with an average of 36.7 gestational weeks. Thirty-six of the patients were born in the Department of Gynecology at the Dokkyo Medical University Hospital and 8 patients were born at other hospital and transferred immediately after birth. Immediately following the delivery, apgar scores of 1 and 5 min were 3 and 6, respectively. The average birth weight was 1585.5±493.6 g, with a range of 770--2,946 g. The breakdown of birth weight included 4 patients weighing \<1,000 g, 17 patients weighing 1,001--1,500 g, 13 patients weighing 1,501--2,000 g, 9 patients weighing 2,001--2,500 g, and 1 patient weighing \>2,500 g at delivery. Regarding methods of delivery, 19 patients were delivered via cesarean section and 19 patients via spontaneous delivery.

Three types of statistical analyses were performed for groups A and B. Significant differences were not identified in any of the general conditions examined with the exception of caesarean section which was statistically significant (P\<0.045). Thus, there were no differences between the two groups with regard to the general state of neonate during time of delivery.

Organ malformations, use of mechanical ventilation, and discharge from NICU
---------------------------------------------------------------------------

Ventilation and surgical treatment as well as discharge from the NICU and prognosis are shown in [Tables II](#tII-mmr-13-03-2457){ref-type="table"} and [III](#tIII-mmr-13-03-2457){ref-type="table"}. Disease manifestations including trisomy 21, 18 and 13, were indicated in the ultrasonography examination during the course of pregnancy, such as intrauterine growth impairment, brain malformation, and congenital heart anomalies. These anomalies were primarily cardiac and brain, and mechanical ventilation as well as surgical procedures were used prior to analysis of outcome and survival ([Tables II](#tII-mmr-13-03-2457){ref-type="table"} and [III](#tIII-mmr-13-03-2457){ref-type="table"}).

As for the congenital heart diseases, 42 of 44 patients (95%) had some types of cardiac disorder. The breakdown include VSD in 37 patients, PDA in 17 patients, atrial septal defect (ASD) in 14 patients, coarctation of the aorta in 8 patients, double outlet right ventricle in 6 patients, endocardial cushion defect in 3 patients, tricuspid atresia in 2 patients and tetralogy of Fallot (TOF) in 2 patients, mitral valve atresia in 2 patients, transposition of great arteries and hypoplastic left heart syndrome in 1 patient with trisomy 18. Although 42 cases had a cardiac problem, only one case with TOF underwent surgery following transfer from another hospital. Diuretic medication was prescribed for the management of the cardiac anomalies. Among the major central nervous malformations, 3 patients with trisomy 18 had complicated brain or spinal anomaly. Two patients had spinal meningocele, 1 patient had holoprosencephaly and 1 patient had Dandy-Walker malformation. Sixteen cases of esophageal atresia were also identified, while 4 cases had umbilical hernia. Surgical treatment of gastric fistula was performed in 8 cases of trisomy 18 with complicated severe esophageal atresia with cardiac anomalies.

Mechanical ventilation was performed in 11 cases in 20 samples (55%) obtained from group A and 18 cases in 24 samples (75%) obtained from group B. Thus, treatment using mechanical ventilation showed an increasing trend between group A and B. The primary reason for ventilation therapy was due to respiratory failure with cardiac failure and management of surgery. In-hospital death at NICU occurred in 35 cases, with 4 cases being transferred from another hospital to undergo surgical treatment and 5 cases that were discharged from the NICU were alive. Alive discharge and hospital transfer were increased in group B. The longest survival case was a female patient who survived \>6 years and 4 months.

Prognosis
---------

Kaplan-Meier survival curves were created ([Figs. 1](#f1-mmr-13-03-2457){ref-type="fig"} and [2](#f2-mmr-13-03-2457){ref-type="fig"}), based on the data obtained from [Table IV](#tIV-mmr-13-03-2457){ref-type="table"}. Vertical and horizontal axes of the two figures are the percentage survival and survival days, respectively, setting the longest survival time at 1 year.

[Fig. 1](#f1-mmr-13-03-2457){ref-type="fig"} shows the curve for all 44 cases, indicating that one group survived for 4--6 months and the other group survived for a longer period of time.

[Fig. 2](#f2-mmr-13-03-2457){ref-type="fig"} is a breakdown of the data shown in [Fig. 1](#f1-mmr-13-03-2457){ref-type="fig"}, showing the percentage survival curves for groups A and B. The difference in the curves between groups A and B are evident. The generalized Wilcoxon test was employed to determine the differences between the two curves. The results showed a statistically significant (\<0.05) p-value of 0.029 (95% confidence interval), indicating a better prognosis for group B in the previous 10 years.

Notably, the two curves showed an increasing tendency of percentage survival during the first 1- to 6-month period ([Fig. 2](#f2-mmr-13-03-2457){ref-type="fig"}). Subsequently, however, the difference in the percentage survival of the two groups indicated a decreasing tendency in the 6-month to 1 year period. We analyzed this tendency using the log-rank test at 180 days and 1 year ([Table IV](#tIV-mmr-13-03-2457){ref-type="table"}). The results of the log-rank test indicated a statistically significant (\<0.05) p-value of 0.036 at the survival point of 180 days. At the point of 1 year as well as the entire investigated period, the difference was not statistically significant (\<0.05) with a p-value of 0.075 and 0.126.

Discussion
==========

In this study, we have examined the prognosis of 44 cases of trisomy 18 identified in our NICU over the course of 21 years from 1992 to 2013. Depending on the timing of birth, the subjects with trisomy 18 were divided into two groups, with group A comprising 20 cases, born during the period of 1992--2002, and group B comprising 24 cases, born during the period of 1992--2012. The aim of the present study was to clarify the characteristics and prognosis for each trisomy 18 case, and to compare and consider the life prognosis of the two groups. A comparison of factors such as chromosome type and gender, as well as gestational age as at the time of birth, birth place, vaginal delivery or cesarean section as method of delivery, and Apgar scores based on the 1- and 5-min value, and birth weight was made for groups A and B. Statistical analysis was conducted using three methods to verify the existence of significant differences for groups A and B regarding trisomy 18 for newborns following birth. The results for the A and B trisomy 18 groups showed that, a significant difference was identified only for cesarean section, whereas no significant difference was identified for other factors with regard to the state of the child at birth. Thus, the two groups were considered uniform. A comparison of the two groups using the Kaplan-Meier curve and generalized Wilcoxon test showed an improvement in prognosis in group B. Thus, the progression of medical intervention during the two periods prior to and following the study period is evident due to the life prognosis of patients with trisomy 18 having improved. However, the results of the log-rank test conducted showed that, although a significant difference was observed in the trisomy 18 prognosis at the time of 180 days after birth, at 1 year and the entire survey period after birth, these significant differences could not be confirmed. Thus, additional studies should be performed to confirm the life prognosis and medical intervention of trisomy 18 for neonatal to infantile periods.

Previously, despite medical treatment the prognosis for patients with trisomy 18 was lethal reason for chromosomal aberration. Trisomies 21 (Down syndrome), 18 (Edwards syndrome) and 13 (Patau syndrome), as well as other chromosomes are associated with various types of severe anomalies of the mainly brain and viscera, and affected neonate usually do not survive infantile period ([@b4-mmr-13-03-2457],[@b5-mmr-13-03-2457]). Additionally, complete autosomal trisomies frequently resulted in non-implantation or miscarriage; thus, chromosomal abnormality cases that survive following birth are primarily trisomies 21, 18 and 13 ([@b8-mmr-13-03-2457]). Jenderny ([@b32-mmr-13-03-2457]) conducted a study on a German population, and revealed that clinically, the majority of trisomies are unborn due to miscarriage. Pregnancy loss rates ranging from 72 to 87% for trisomy 18 were demonstrated by Sibiude *et al* ([@b33-mmr-13-03-2457]) and between 49 and 66% by Lakovschek *et al* ([@b34-mmr-13-03-2457]) for trisomy 13, respectively. It has been previously identified that trisomy 18 and 13 are the most common trisomies following trisomy 21 ([@b35-mmr-13-03-2457]), with trisomy 18 being the second common trisomy after trisomy 21. Baird and Sadovnick ([@b36-mmr-13-03-2457]) and Noble ([@b37-mmr-13-03-2457]) reported that the average life expectancy of Down syndrome was \>50 years old due to medical advances in medically advanced countries. However, to the best of our knowledge, the majority of live-born infants with trisomy 18 and 13 survive \<1 year and do not survive to adulthood. In our study, only 5 of the 44 patients survived beyond 1 year of age. Generally, the prognosis of trisomy 18 and 13 are lethal, but long-term survival cases of such trisomies have been sporadically observed. Kelly *et al* ([@b38-mmr-13-03-2457]) described 20-year-old women and Torres Hinojal *et al* ([@b39-mmr-13-03-2457]) reported a 14-year-old patient with trisomy 18. Another case report of long survival of cases of trisomy 18 was conducted by Petek *et al* ([@b40-mmr-13-03-2457]) who reported on a 19-year-old female and by Smith *et al* ([@b41-mmr-13-03-2457]) who reported on an 11-year-old female patient and a 21-year-old female patient ([@b42-mmr-13-03-2457]). A search of the literature yielded ≥10 previously reported cases of affected children with trisomy 18, aged \>10 years ([@b43-mmr-13-03-2457]--[@b45-mmr-13-03-2457]). In our patient, the oldest individual with trisomy 18 was a 6-year and 4-month-old female patient with severe intellectual and psychomotor disorder.

Patients with trisomy 18 who show long-term survival present severe psychomotor delay ([@b46-mmr-13-03-2457]). For such cases, aggressive medical treatment in the intensive care unit is controversial as life prognosis is lethal. Only a few studies of patients being managed at NICU have been previously reported. Of these, Kosho *et al* ([@b14-mmr-13-03-2457],[@b31-mmr-13-03-2457]) demonstrated that restricted and intensive medical treatments in NICU are valuable in the form of genetic counseling. Since the 1980\'s, resuscitation and surgical treatments for trisomy 18 have been considered from the standpoints of medical ethics and consideration of quality of life for patients as well as parents and their families, medical economic issues, and medical environment in each countries. In Japan, Nishida and Sakamoto ([@b30-mmr-13-03-2457]) suggested a policy of \'no treatments beyond current treatments\' for treatment of newborn infants in 1992. Paris *et al* ([@b47-mmr-13-03-2457]) also indicated ambiguous ethical issues in the use of life-prolonging interventions for an infant with trisomy 18 in 1992. However, long survival of individuals with chromosomal abnormalities including trisomy 18 and 13, owing to medical progression has since been identified. Notably, treatment policy has also led to gradually changes in medical, sociological, and technical progression. The 4th edition of Smith\'s textbook in 1988 supports the \'limitation of all medical means for prolongation of life for trisomy 18\' ([@b48-mmr-13-03-2457]). However, the 7th edition of the same textbook in 2013, supports that \'limitation of extraordinary medical means should be seriously considered\'. In addition, it advocates that the personal feelings of the parents and the individual circumstances of each infant be taken into consideration ([@b49-mmr-13-03-2457]).

The survival of patients with trisomy 18 and the survival rate from several countries for the period 1967--2010 have been reported in the present study. A long survival period of over 6 months is difficult for patients with trisomy 18, as indicated by Lin *et al* in 2006 ([@b52-mmr-13-03-2457]) and Weber *et al* ([@b50-mmr-13-03-2457]) in 1967. On the other hand, the recent findings of Kosho *et al* ([@b14-mmr-13-03-2457]) and those of our group ([@b8-mmr-13-03-2457]) for populations of Japan, revealed improved life outcome of trisomy 18. Studies have been recently conducted to investigate treatment procedures and outcome for trisomy 18 ([@b53-mmr-13-03-2457]). Mechanical ventilation treatment was performed in 29 of 44 patients (65.9%) by in the present study and the percentage was increased in group B. Paris *et al* ([@b47-mmr-13-03-2457]) suggested that physicians should be attentive with regard to concentration treatment including ventilation therapy and life-prolonging intervention. Bos *et al* ([@b29-mmr-13-03-2457]) also report avoidance of emergency surgery in newborns with trisomy 18. In the present study, patients underwent ventilation therapy owing to respiratory failure and general management. Fenton ([@b54-mmr-13-03-2457]) suggested factors such as quality of life for determining treatment for trisomy 18. On the other hand, surgical treatment is preferred following informed consent with counseling from the family support meeting ([@b55-mmr-13-03-2457]). Kosho ([@b31-mmr-13-03-2457]) emphasized care of children with trisomy 18 in Japan. Information such as cesarean section ([@b56-mmr-13-03-2457]), general condition ([@b57-mmr-13-03-2457]), health care ([@b58-mmr-13-03-2457]), family ([@b59-mmr-13-03-2457]) and neonatal experience ([@b60-mmr-13-03-2457]) care were important in the treatment of cases with trisomy 18. However, no clear guideline regarding treatment policy and strategy has been established. In Japan, the surgical treatment of a variety of congenital cardiac diseases ([@b61-mmr-13-03-2457]--[@b65-mmr-13-03-2457]) and esophageal atresia ([@b66-mmr-13-03-2457]) have been performed in patients with trisomy 18. In addition, treatment for apnea and epilepsy ([@b67-mmr-13-03-2457]--[@b69-mmr-13-03-2457]) were also provided. Graham *et al* ([@b70-mmr-13-03-2457]) summarized 35 cases of cardiac surgery with trisomy 18 and 13, with increased discharge from the hospital. However, prognosis and quality of life of those patients remain unclear. Janvier *et al* ([@b71-mmr-13-03-2457]) discussed the issue of ethics regarding an infant-associated VSD. Kaneko *et al* ([@b62-mmr-13-03-2457]) reported 17 cases of trisomy 18 with cardiac surgery and 14 cases (82%) were discharged from NICU leading to a conclusion that it was effective in decreasing mortality in NICU due to cardiac failure. NICU management with ventilation and surgical procedures has potential to improve the short-term outcome of \<1 year in trisomy 18. In the present study, an improvement in the outcome of 6 months from delivery by various treatments including mechanical ventilation and surgical procedure was observed. However, additional studies on a larger number of cases should be performed concerning treatment strategy and genetic counseling to the family with a newborn with trisomy 18.

Although the present study had a small sample size, our data provide one of the larger single-center studies currently available. The results of the present study provide information concerning genetic counseling for parents and their families and life prognosis, prior to applying intensive management to newborns with trisomy 18
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###### 

Clinical details at delivery of newborns with trisomy 18 included in this study (n=44).

  Characteristics           No.   Entire investigation period (1992--2012)   No.                       Group A (1992--2002)   No.   Group B (2003--2012)      P-value groups A vs. B
  ------------------------- ----- ------------------------------------------ ------------------------- ---------------------- ----- ------------------------- -------------------------------------------------------
  No. of patients           --    6,183                                      --                        2,928                  --    3,255                     --
  Trisomy 18 cases          44    44                                         20                        20                     24    24                        --
  Karyotype                 44                                               20                                               24                              0.493[a](#tfn2-mmr-13-03-2457){ref-type="table-fn"}
   Full                           42                                                                   20                           22                        
   Others                         2                                                                    0                            2                         
  Gender                    44                                               20                                               24                              \>0.999[a](#tfn2-mmr-13-03-2457){ref-type="table-fn"}
   Male                           16                                                                   7                            9                         
   Female                         28                                                                   13                           15                        
  Term of delivery (week)   44                                               20                                               24                              
   Mean ± SD                      36.7±3.2                                                             37.3±3.2                     36.3±3.2                  0.309[b](#tfn3-mmr-13-03-2457){ref-type="table-fn"}
   Median (IQR)                   37.0 (34.0, 39.0)                                                    37.5 (35.0, 39.8)            36.5 (34.0, 39.0)         0.374[c](#tfn4-mmr-13-03-2457){ref-type="table-fn"}
  Delivery place            44                                               20                                               24                              0.436[a](#tfn2-mmr-13-03-2457){ref-type="table-fn"}
   Our hospital                   36                                                                   15                           21                        
   Other hospital                 8                                                                    5                            3                         
  Delivery                  38                                               15                                               23                              0.045[a](#tfn2-mmr-13-03-2457){ref-type="table-fn"}
   Cesarean section               19                                                                   4                            15                        
   Vaginally                      19                                                                   11                           8                         
  Apgar score (point)                                                                                                                                         
   1 min                    37                                               14                                               23                              
    Mean ± SD                     3.4±2.1                                                              3.2±2.2                      3.6±2.1                   0.631[b](#tfn3-mmr-13-03-2457){ref-type="table-fn"}
    Median (IQR)                  3.0 (2.0, 5.0)                                                       2.5 (1.8, 5.0)               3.0 (2.0, 5.0)            0.546[c](#tfn4-mmr-13-03-2457){ref-type="table-fn"}
   5 min                    35                                               13                                               22                              
    Mean ± SD                     6.0±2.0                                                              5.7±2.0                      6.2±2.0                   0.492[b](#tfn3-mmr-13-03-2457){ref-type="table-fn"}
    Median (IQR)                  6.0 (5.0, 7.0)                                                       5.0 (4.0, 6.5)               6.0 (5.0, 7.0)            0.180[c](#tfn4-mmr-13-03-2457){ref-type="table-fn"}
  Birth weight (g)          44                                               20                                               24                              
   Mean ± SD                      1585.5±493.6                                                         1654.9±576.8                 1527.8±415.9              0.402[b](#tfn3-mmr-13-03-2457){ref-type="table-fn"}
   Median (IQR)                   1536.0 (1186.5, 1969.5)                    1552.0 (1175.0, 2164.0)                                1519.0 (1186.5, 1851.0)   0.525[c](#tfn4-mmr-13-03-2457){ref-type="table-fn"}
  Categorical data          44                                               20                                               24                              0.525[c](#tfn4-mmr-13-03-2457){ref-type="table-fn"}
   \<1,000                        4                                                                    2                            2                         
   1,000--1,500                   17                                                                   7                            10                        
   1,501--2,000                   13                                                                   5                            8                         
   2,001--2,500                   9                                                                    5                            4                         
   \<2.500                        1                                                                    1                            0                         

No., %; mean ± standard deviation (SD); median \[interquartile range (IQR)\]. P--value;

Fisher\'s exact test;

unpaired t-test;

Mann-Whitney U test.

###### 

Organ malformations, use of mechanical ventilation, surgical treatments and discharge from NICU for patients with trisomy 18 (group A, 1992--2002, n=20).

  (Group A) Patients   Major organ malformations   Mechanical ventilation   Surgical treatment         Discharge from NICU (D, dead; A, alive; T, transfer)   Survival (days)
  -------------------- --------------------------- ------------------------ -------------------------- ------------------------------------------------------ -----------------
  1                    TOF PDA EA                  −                                                   D                                                      0
  2                    ECD IAA EA                  \+                                                  D                                                      0
  3                    TGA ECD                     −                                                   D                                                      0
                       Anal atresia                                                                                                                           
                       Defects of both thumb                                                                                                                  
  4                    PDA CoA EA                  −                                                   D                                                      2
  5                    VSD PDA UH                  \+                       Repair UH                  D                                                      3
                       Urachal remnants                                                                                                                       
  6                    VSD EA                      −                                                   D                                                      3
  7                    EA                          \+                       Gastric fistula            D                                                      8
  8                    VSD ASD PDA EA              \+                                                  D                                                      17
  9                    VSD EA                      −                        Gastric fistula            D                                                      27
  10                   VSD CoA                     \+                       Colostomy                  D                                                      30
                       Cleft lip and palate                                 Intestinal segmentectomy                                                          
  11                   VSD ASD EA                  \+                                                  D                                                      47
  12                   VSD PDA                     \+                                                  D                                                      53
  13                   VSD EA                      \+                       Gastric fistula            D                                                      56
  14                   ASD PDA CoA UH              \+                                                  D                                                      78
  15                   VSD ASD PDA UH              \+                                                  D                                                      83
  16                   VSD ASD                     −                                                   A                                                      102
  17                   EA                          −                                                   D                                                      116
  18                   TA                          −                                                   D                                                      202
  19                   VSD DWM                     \+                                                  D                                                      414
  20                   VSD PDA                     −                                                   A                                                      2311
  Total                                            +:11/−:9                                            D:18/A:2                                               

VSD, ventriculoseptal defect; ASD, atrial septal defect; PDA, patent ductus arteriosus; CoA, coarctation of the aorta; DORV, double-outlet right ventricle; ECD, endocardial cushion defect; TOF, tetralogy of Fallot; IAA, interruption of aortic arch; TGA, transposition of great arteries; TA, tricuspid atresia; UH, umbilical hernia; EA, esophageal atresia; DWM, Dandy-Walker malformation; NICU, neonatal intensive care unit.

###### 

Organ malformations, use of mechanical ventilation, surgical treatments and discharge from NICU for patients with trisomy 18 (group B, 2003--2012, n=24).

  Group B Patients   Major organ malformations   Mechanical ventilation   Surgical treatment          Discharge from NICU (D, dead; A, alive; T, transfer)   Survival (days)
  ------------------ --------------------------- ------------------------ --------------------------- ------------------------------------------------------ -----------------
  21                 n.d.                        \+                                                   D                                                      0
  22                 VSD ASD PDA IAA EA          \+                                                   D                                                      1
                     Cleft lip and palate                                                                                                                    
                     Spurious meningocele                                                                                                                    
  23                 ASD TA                      \+                                                   D                                                      4
  24                 ECD                         \+                       Gastric fistula             D                                                      8
  25                 VSD PDA                     −                                                    D                                                      25
                     Cleft lip and palate                                                                                                                    
  26                 VSD ASD DORV UH             \+                                                   D                                                      45
                     Defects of right radius                                                                                                                 
  27                 VSD CoA                     \+                                                   A                                                      51
                     Holoprosencephaly                                                                                                                       
  28                 VSD CoA                     \+                                                   D                                                      60
  29                 VSD ASD PDA EA              \+                       Gastric fistula             D                                                      70
  30                 VSD MS EA                   \+                       Gastric fistula             T                                                      92
  31                 VSD ASD PDA                 \+                                                   D                                                      96
  32                 VSD PDA CDH                 \+                       Biliary duct drainage       D                                                      108
                     Biliary duct dilatation                                                                                                                 
  33                 VSD ASD EA                  \+                       Gastric fistula             D                                                      116
  34                 TOF                         −                        Blalock-Taussig operation   T                                                      127
  35                 VSD ASD CoA                 −                                                    D                                                      132
  36                 VSD ASD                     −                                                    A                                                      162
                     Laryngeal malacia                                                                                                                       
  37                 VSD ASD PDA CoA             \+                                                   D                                                      250
  38                 VSD PDA                     −                                                    D                                                      250
                     Pyloric stenosis                                                                                                                        
  39                 PDA DORV EA                 −                                                    A                                                      263
  40                 DORV MA HLHS                \+                                                   T                                                      263
  41                 DORV                        \+                                                   D                                                      309
                     Spurious meningocele                                                                                                                    
                     Defects of radius                                                                                                                       
  42                 VSD PDA                     \+                                                   D                                                      420
  43                 VSD DORV                    \+                                                   T                                                      667
  44                 VSD CoA VORV EA             \+                       Gastric fistula             D                                                      699
                     Imperforate anus                                                                                                                        
  Total                                          +:18/−:6                                             D:17/T:4/A:3                                           

VSD, ventriculoseptal defect; ASD, atrial septal defect; PDA, patent ductus arteriosus; CoA, coarctation of the aorta; DORV, double-outlet right ventricle; ECD, endocardial cushion defect; TOF, tetralogy of Fallot; IAA, interruption of aortic arch; TA, tricuspid atresia; MA, mitral valve atresia; HLHS, hypoplastic left heart syndrome; UH, umbilical hernia; EA, esophageal atresia; CDH, congenital diaphragmatic hernia; NICU, neonatal intensive care unit; n.d, no data.

###### 

The analyzed data of the log-rank test at each observation period (group A vs. B).

  Survival days     Chi-square distribution   df   p-value
  ----------------- ------------------------- ---- ---------
  180               4.381                     1    0.036
  365               3.173                     1    0.075
  Observation end   2.344                     1    0.126

###### 

Survival rate and prognosis of trisomy 18 in the present study compared to previously reported data.

  Variables                Multi-center study              Queensland, Australia             Denmark                           Utah, USA                      England                           Scotland                          Altanta, USA                      Taiwan                            Japan                             Japan                            All investigated period               Group A               Group B
  ------------------------ ------------------------------- --------------------------------- --------------------------------- ------------------------------ --------------------------------- --------------------------------- --------------------------------- --------------------------------- --------------------------------- -------------------------------- ------------------------------------- --------------------- --------------
  Author/(Refs.)           Weber ([@b50-mmr-13-03-2457])   Carter                            Goldstein and                     Root and                       Embleton                          Brewer                            Rasmussen                         Lin                               Kosho                             Imataka                          Our study                             Our study             Our study
                                                           *et al* ([@b51-mmr-13-03-2457])   Nielsen ([@b10-mmr-13-03-2457])   Carey ([@b9-mmr-13-03-2457])   *et al* ([@b17-mmr-13-03-2457])   *et al* ([@b16-mmr-13-03-2457])   *et al* ([@b13-mmr-13-03-2457])   *et al* ([@b52-mmr-13-03-2457])   *et al* ([@b14-mmr-13-03-2457])   *et al* ([@b8-mmr-13-03-2457])                                                               
  Year                     1967                            1985                              1988                              1994                           1996                              2002                              2003                              2006                              2006                              2007                             (1992--2012)                          (1992--2002)          (2003--2012)
  No.                      n=192                           n=43                              n=76                              n=64                           n=34                              n=84                              n=114                             n=39                              n=24                              n=179                            n=44                                  n=20                  n=24
  Survival time            \% survival                     \% survival                       \% survival                       \% survival                    \% survival                       \% survival                       \% survival                       \% survival                       \% survival                       \% survival                      \% survival                           \% survival           \% survival
    \>24 h                 98                              60                                60                                86                             70                                88                                86                                95                                95.8                              85.16                            90.9                                  85                    95.8
    \>7 days               89                              35                                44                                45                             n.d.                              43                                63                                46                                87.5                              68.99                            79.5                                  70                    87.5
    \>1 month              72                              11                                21                                34                             15                                25                                39                                16                                83.3                              43.75                            65.9                                  50                    79.2
    \>2 months             52                              8                                 n.d.                              22                             n.d.                              n.d.                              30                                11                                62.5                              35.92                            52.3                                  35                    66.7
    \>6 months             13                              5                                 3                                 9                              n.d.                              n.d.                              11                                3                                 45.8                              17.83                            25                                    15                    33.3
    1 year \<              8                               4                                 n.d.                              5                              0                                 2                                 8                                 3                                 25                                9.09                             11.4                                  10                    12.5
  Median survival (days)   n.d.                            5                                 6                                 4                              3                                 6                                 14.5                              36                                152.5                             n.d.                             74.0 (10.3, 192.0) 38.5 (3.0, 97.3)   112.0 (46.5, 259.8)   

Mann-Whitney U test, group A vs. B, p-value 0.033. n.d., no data; median \[interquartile range (IQR)\].
